APAC Uterine Cancer Therapeutics & Diagnostics Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| Historical Data Period | 2019 - 2022 |
| CAGR | 2.50 % |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
APAC Uterine Cancer Therapeutics & Diagnostics Market Analysis
The Asia-Pacific Uterine Cancer Therapeutics & Diagnostics Market is expected to register a CAGR of 2.5% during the forecast period. The major factors driving the growth of the market in the Asia region is due to growing awareness about Uterine diseases and their available therapies, increasing health care expenditure and innovation in drug development, and subsequent technological advancements.
According to Cancer Australia, estimated that in 2016, there were about 527 deaths from uterine cancer in Australia. In 2019, it was estimated at around 562 deaths. In addition, it also stated that the risk of a female dying from uterine cancer will be 1 in 205.
Furthermore, governments are provoking awareness programs in certain Asia-Pacific regions. With the growing focus of the government and the healthcare providers, it has been indicated that the market will grow rapidly over the forecast period.
APAC Uterine Cancer Therapeutics & Diagnostics Market Trends
This section covers the major market trends shaping the APAC Uterine Cancer Therapeutics & Diagnostics Market according to our research experts:
Endometrial Adenocarcinoma is Expected to Witness Highest Growth Over the Forecast Period in the Asia-Pacific Uterine Cancer Therapeutics & Diagnostics Market
The major factors driving the growth of the segment is due to the growing burden of endometrial adenocarcinoma. For instance, as per Cancer Australia, in 2019, it is estimated that the age-standardized incidence rate of uterine cancer was about 20 cases per 100,000 females in Australia. The incidence rate for uterine cancer was expected to increase with age, peaking at age group 65–69.
Furthermore, as per the Journal of Gynecological Oncology 2020, endometrial cancer is a major gynecologic malignancy with the highest rate among patients with gynecologic malignant tumors in Japan. In Japan, the age-adjusted mortality rate of endometrial cancer was 2.0 in 2017. In addition, in Australia, there were about 3,115 (4.7%) new cases of uterine cancer diagnosed in 2019 as per Cancer Australia. Thus, owing to the above factors the segment is expected to show growth in the coming years.
APAC Uterine Cancer Therapeutics & Diagnostics Industry Overview
The Asia-Pacific Uterine Cancer Therapeutics & Diagnostics Market is consolidated competitive and most of the companies dealing with this market are the global players. However, with the rising technological advancements, smaller companies are also focusing on market penetration and are taking efforts to grab enough market share. Some of the companies involved in the market are Merck & Co., Inc, Eisai.Co.Ltd, Abbott Laboratories, F. Hoffmann-La Roche Ltd, Takeda Pharmaceutical Company Limited, Siemens Healthcare Inc, GlaxoSmithKline Plc and Novartis AG.
APAC Uterine Cancer Therapeutics & Diagnostics Market Leaders
-
Merck & Co., Inc
-
Eisai.Co.Ltd
-
Abbott Laboratories
-
F. Hoffmann-La Roche Ltd
-
Takeda Pharmaceutical Company Limited
*Disclaimer: Major Players sorted in no particular order
APAC Uterine Cancer Therapeutics & Diagnostics Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Growing Awareness About Uterine Diseases and Their Available Therapies
- 4.2.2 Increasing Health Care Expenditure
- 4.2.3 Innovation in Drug Development and Subsequent Technological Advancements
-
4.3 Market Restraints
- 4.3.1 Low Success Rate in Clinical Trials for Cancer Drugs
- 4.3.2 High Cost Associated With the Treatment
-
4.4 Porter's Five Force Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
-
5.1 By Cancer Type
- 5.1.1 Endometrial Adenocarcinoma
- 5.1.2 Adenosquamous Carcinoma
- 5.1.3 Papillary Serous Carcinoma
- 5.1.4 Uterine Sarcoma
-
5.2 By Product
- 5.2.1 Therapeutics
- 5.2.1.1 Surgery
- 5.2.1.2 Immunotherapy
- 5.2.1.3 Radiation Therapy
- 5.2.1.4 Chemotherapy
- 5.2.1.5 Other Therapeutics
- 5.2.2 Diagnostics
- 5.2.2.1 Biopsy
- 5.2.2.2 Pelvic Ultrasound
- 5.2.2.3 Hysteroscopy
- 5.2.2.4 Dilation and Curettage
- 5.2.2.5 CT Scan
-
5.3 Geography
- 5.3.1 Asia-Pacific
- 5.3.1.1 China
- 5.3.1.2 Japan
- 5.3.1.3 India
- 5.3.1.4 Australia
- 5.3.1.5 South Korea
- 5.3.1.6 Rest of Asia-Pacific
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 Merck & Co., Inc
- 6.1.2 Eisai.Co.Ltd
- 6.1.3 Abbott Laboratories
- 6.1.4 F. Hoffmann-La Roche Ltd
- 6.1.5 Takeda Pharmaceutical Company Limited
- 6.1.6 Siemens Healthcare Inc
- 6.1.7 GlaxoSmithKline Plc
- 6.1.8 Novartis AG
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityAPAC Uterine Cancer Therapeutics & Diagnostics Industry Segmentation
As per the scope of the report, uterine cancer is a common form of cancer of the female reproductive system that initiates in the lining of the uterus. The Asia-Pacific Uterine Cancer Therapeutics & Diagnostics Market is segmented by type of cancer, product, and geography.
| By Cancer Type | Endometrial Adenocarcinoma | |
| Adenosquamous Carcinoma | ||
| Papillary Serous Carcinoma | ||
| Uterine Sarcoma | ||
| By Product | Therapeutics | Surgery |
| Immunotherapy | ||
| Radiation Therapy | ||
| Chemotherapy | ||
| Other Therapeutics | ||
| By Product | Diagnostics | Biopsy |
| Pelvic Ultrasound | ||
| Hysteroscopy | ||
| Dilation and Curettage | ||
| CT Scan | ||
| Geography | Asia-Pacific | China |
| Japan | ||
| India | ||
| Australia | ||
| South Korea | ||
| Rest of Asia-Pacific |
APAC Uterine Cancer Therapeutics & Diagnostics Market Research FAQs
What is the current APAC Uterine Cancer Therapeutics & Diagnostics Market size?
The APAC Uterine Cancer Therapeutics & Diagnostics Market is projected to register a CAGR of 2.5% during the forecast period (2024-2029)
Who are the key players in APAC Uterine Cancer Therapeutics & Diagnostics Market?
Merck & Co., Inc, Eisai.Co.Ltd, Abbott Laboratories, F. Hoffmann-La Roche Ltd and Takeda Pharmaceutical Company Limited are the major companies operating in the APAC Uterine Cancer Therapeutics & Diagnostics Market.
What years does this APAC Uterine Cancer Therapeutics & Diagnostics Market cover?
The report covers the APAC Uterine Cancer Therapeutics & Diagnostics Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the APAC Uterine Cancer Therapeutics & Diagnostics Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
APAC Uterine Cancer Therapeutics & Diagnostics Industry Report
Statistics for the 2024 APAC Uterine Cancer Therapeutics & Diagnostics market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. APAC Uterine Cancer Therapeutics & Diagnostics analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
